GSK GlaxoSmithKline - Swine Flu Stocks to Watch
GSK GlaxoSmithKline Swine Flu (NYSE: GSK; LSE: GSK.L)
With advanced orders from the UK government for over 60 million doses of its flu vaccine, GlaxoSmithKline UK is preparing to sell £3bn worth of swine flu drugs this year.
Glaxo is Britain’s biggest pharmaceutical supplier and has deals with world governments for its antiviral treatment Relenza, which can relieve swine flu symptoms.
Worldwide sales from the two drugs are expected to reach £3bn by January 2010 and GSK is also donating 50 million doses to the WHO to distribute to poorer nations.
The world’s second-largest drug company has secured orders from 16 countries for 195 million doses of the vaccine it is developing against the H1N1 virus – influenza virus - and has other products for prevention and to treat swine flu symptoms currently in the final trial stages.
Since GSK GlaxoSmithKline controls the largest production and distribution network, top biotech companies normally join forces with Glaxo to exceed their production and distribution capabilities.
Some of the top pharmaceutical companies in the swine flu research include: AVI Biopharma (AVII), Baxter International (BAX), Generex Biotechnology (GNBT), Antigenics (AGEN), Quidel Corporation (QDEL).
Latest Discoveries - Effects of Tamiflu and Relenza in Children
GlaxoSmithKline Company Overview
GlaxoSmithKline are arguably the largest research-based pharmaceutical company in the world. Roche is it’s direct competitor in the fight for the swine flu antiviral market share with their top sales Tamiflu.
With a mission to improve the quality of human life by enabling people to do more, feel better and live longer GlaxoSmithKline are committed to tackling the three “priority” diseases identified by the World Health Organization: HIV/AIDS, tuberculosis and malaria.
Employing nearly 100,000 people in over 100 countries GlaxoSmithKline produces almost 4 billion products every year and supplies nearly one quarter of the worlds vaccines with another 20 vaccines currently in development.
Glaxo had a turnover of over 24,352 Million pounds in 2008 and is looking to remain as one of the top pharmaceutical companies. GlaxoSmithKline share price has increased roughly 15% since April 2009, but GlaxoSmithKline stock is still 40% lower than the 5-year highest achieved on 2007.
This post has 1 comments
August 14th, 2009
I’ve been a pharmacist all my life and remember investing into Glaxo back in 1990 when I move to New York. I don’t think I paid more that 10$ a share. I’ve been a big fan of Glaxosmithkline using their products and all for a few decades now. Till now I have not sold any or bought any more but sometimes I wish I did . Good luck Glaxo on any new developements with the swine flu research.
Trackbacks